Implications of a HbA1c based diabetes screening on prevalence and impact of dysglycemia in patients with COVID-19.
Lukas Van BaalJohanna ReinoldSven BensonAnke DiehlOliver WitzkeDagmar FuhrerSusanne TanPublished in: The Journal of clinical endocrinology and metabolism (2022)
Pandemic conditions may hamper dysglycemia detection rate and in consequence the awareness of individual patient risk for COVID-19 severity. A systematic diabetes screening including HbA1c reduces underdiagnosis of previously unknown or new onset dysglycemia, enhances the quality of risk estimation and access of patients at risk to a diabetes-specific intervention.
Keyphrases
- type diabetes
- cardiovascular disease
- glycemic control
- end stage renal disease
- newly diagnosed
- coronavirus disease
- sars cov
- randomized controlled trial
- ejection fraction
- chronic kidney disease
- risk factors
- prognostic factors
- adipose tissue
- skeletal muscle
- patient reported
- real time pcr
- respiratory syndrome coronavirus